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Simultaneous neoadjuvant 
radiochemotherapy with 
capecitabine and oxaliplatin for 
locally advanced rectal cancer
Treatment outcome outside clinical trials
Neoadjuvant chemoradiotherapy is a stan-
dard treatment for locally advanced rectal 
carcinoma (LARC), especially of the lower 
two thirds of the organ. This treatment ap-
proach offers the best locoregional control 
and a chance for sphincter preservation in 
tumours located less that 6 cm from the 
anal verge [5, 6, 7, 15, 38]. Numerous che-
motherapeutic schemes have been test-
ed over the last decade for simultaneous 
administration with external beam ra-
diotherapy (EBRT), aiming to improve 
the rates of locoregional control, sphinc-
ter-sparing surgery and diminish distant 
failure [30, 33, 37]. However, it could not 
be clarified yet which chemotherapy regi-
men should be applied in order to achieve 
the maximal therapeutic benefit for the 
patient, i.e: an excellent tumour control 
while providing an acceptable quality of 
life during and after the treatment [44].
Five-fluorouracil (5-FU) based chemo-
therapy concurrent to EBRT is the current 
standard neoadjuvant scheme, which was 
introduced over two decades ago into the 
treatment of LARC [6] in order to im-
prove local control after radical surgery. 
An oral pro-drug of 5-FU, capecitabine, 
has been lately developed and might be 
more selectively converted into active 5-
FU, especially in irradiated tumour tissue 
[39]. This drug has demonstrated favour-
able results in comparison to intravenous 
5-FU with regard to tumouricidal effects 
and toxicity profile, while being conve-
nient for administration in an outpatient 
setting. In the clinical trials (CTR), all 
known side effects of 5-FU have been also 
present by administration of capecitabine, 
however, with less diarrhoea, nausea and 
high-grade oral mucositis and neutrope-
nia, but with an increased rate of hyperbil-
irubinemia and hand–foot syndrome [24, 
43]. A final report of the first random-
ized comparison of capecitabine versus 5-
FU in combination with irradiation is yet 
awaited [46].
In the treatment of metastatic colorec-
tal cancer newer generation of chemo-
therapeutics including oxaliplatin have 
been assessed and demonstrated superior 
tumour response rates than single agent 
5-FU regimens or its combination with 
either folinic acid or leucovorin [8, 11]. 
Considering the radiosensitizing effects 
of capecitabine and oxaliplatin in vitro 
[10, 45], simultaneous application of both 
substances with EBRT was consequent-
ly examined in phase I and II trials in the 
treatment of LACR [9, 17, 20, 21, 26, 29, 
35, 36]. Several of those trials have dem-
onstrated a promising efficacy and limited 
toxicity profile, leading to the quick adop-
tion of this new regimen in the treatment 
of LARC outside CTR. However, as it was 
recently discussed by Bekelman et al. [4], 
the trials may have limited generalizabil-
ity beyond the setting and subpopulation 
in which the study is conducted. Thus, we 
analyzed retrospectively the efficacy and 
toxicity of this chemoradiotherapy regi-
men in patients treated outside CTR.
Patients and methods
All consecutive patients with histological-
ly confirmed adenocarcinoma of the rec-
tum of stage II or III according to UICC-
TNM classification, treated in neoadju-
vant intention from January 2005 to De-
cember 2008 with capecitabine, oxalipla-
tin and EBRT in the University Hospital 
Basel were evaluated. Pretreatment assess-
ment included a complete history, physi-
cal examination, blood count, renal and 
liver function tests, rigid rectoscopy, biop-
sy, colonoscopy, endorectal ultrasonogra-
phy, computed tomography (CT) of the 
thorax or a chest x-ray, CT of abdomen 
and pelvis, and, in some patients, pelvic 
magnetic resonance imaging.
Treatment
Chemotherapy
Treatment was started upon completion 
of the diagnostic procedures. If the start 
of EBRT had more than 14 days delay, 
chemotherapy was started prior to irra-
diation according to the XELOX scheme: 
capecitabine 1,000 mg/m2 twice dai-
ly (b.i.d.) on days 1–14 and oxaliplatin 
130 mg/m2 on day 1, repeated once again 
on day 22 if still no irradiation followed. 
As soon as EBRT was started, chemother-
apy was applied according to the CAPOX 
schedule (capecitabine 825 mg/m2 b.i.d. 
on irradiation days 1–14 and 22–35, oxali-
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platin 50 mg/m2 on irradiation days 1, 8, 
22 and 29).
Radiotherapy
Megavoltage equipment was used with 
6/10/18 MV. Patients were immobilized in 
the prone position using a belly board. All 
patients received individual three-dimen-
sional CT-based treatment planning. Ra-
diotherapy was delivered through three 
to four portal fields to the tumour, corre-
sponding lymphatic region and perirec-
tal soft tissue structures at risk of micro-
scopic disease. All patients received 45–
50.5 Gy total dose, given in daily fractions 
of 1.8 Gy, 5 times a week.
Surgery
Four to six weeks after completion of the 
chemoradiotherapy, radical surgery en-
compassing total mesorectal excision 
(TME) was performed according to a 
standardised technique as the preferred 
type of radical resection, with sphincter 
preservation whenever feasible.
Adjuvant chemotherapy
Adjuvant chemotherapy was recommend-
ed for all patients according to the NCCN 
(National Comprehensive Cancer Net-
work) guidelines. The choice of the che-
motherapy regimen was at the discretion 
of the medical oncologist. Generally, in 
case of complete or near complete tumour 
regression, further 4–6 courses of XELOX 
regimen were recommended.
Evaluation of efficacy and safety
Efficacy
The extent of residual tumour in the sur-
gical specimen was classified according to 
the UICC-TNM staging system and then 
compared to the tumour stage determined 
after the pretreatment evaluation. The his-
tological regression assessment was per-
formed using the grading criteria estab-
lished by Dworak et al. [14]. In addition, 
the rates of sphincter preservative sur-
gery, R0 resection (circumferential mar-
gins ≥ 2 mm) and the rates of locoregion-
al and distant relapses were estimated as 
well.
Safety
All reported acute treatment-related tox-
icities were registered and graded ac-
cording to Common Toxicity Criteria 
from National Cancer Institute, Version 
2.0 [41]. The follow-up was conducted 
by a medical oncologist as demonstrat-
Tab. 1 Posttreatment surveillance
  Months after completion of the treatment
3 6 12 18 24 30 36 42 48 60
History and physical examination, CEA + + + + + + + + + +
Rectoscopy, sigmoidoscopy  + + + +
Colonoscopy   +    +    
Chest, abdominal and pelvic computed 
tomography (CT) scana
  +  +  +  + +
CEA carcinoembryonic antigen a Annual CT scan could be replaced by a regular abdominal ultrasound, if the 
baseline CT scan was without abnormalities and there were no other findings during the follow-up suggestive 
for a recurrence.
Tab. 2 Baseline characteristics of the 
34 patients
Baseline characteristics Patients 
(n, %)
Age (years)  
< 50 4 (12)
50–70 17 (50)
> 70 13 (38)
Sex  
Male 25 (74)
Female 9 (26)
Tumour location  
Upper third 3 (9)
Middle third 16 (47)
Lower third 15 (44)
TNM stage  
T2 2 (6)
T3 25 (74)
T4 7 (20)
N0 13 (38)
N1–2 21 (62)
Histological grading  
Well differentiated 1 (4)
Moderately differentiated 29 (86)
Poorly differentiated 4 (12)
Tab. 3 Stage migration after the neoadjuvant radiochemotherapy
CS II II III III III III III
cTNM T3N0M0 T4N0M0 T2N1M0 T3N1M0 T4N1M0 T3N2M0 T4N2M0
ypTNM (n) (n) (n) (n) (n) (n) (n)
T0N0M0 2a 1a 1a 1a    
T1N0M0 1a   1a    
T2N0M0 3a 1a  2a 1a   
T3N0M0 3b  1a 2a 1a 1a 1a
T4N0M0 1b       
T0N1M0    1b    
T3N1M0 1c   3b  2a  
T4N1M0     1b   
T3N2M1    1c    
CS initial clinical stage according to UICC-TNM classification; cTNM initial tumour stage according to UICC-TNM 
classification; ypTNM UICC-TNM stage of the pathological specimen. aRegression of initial clinical stage, binitial 
clinical stage remained unchanged, cpathological stage is more advanced than clinical stage.
Tab. 4 Tumour regression grade after radiochemotherapy according to Dworak
Grade Tumour regression Patients
(n)
Proportion
(%)
0 No regression 1 3
1 Minimal regression 9 27.3
2 Moderate regression 12 36.4
3 Good regression 6 18.2
4 Complete regression 5 15.1
378 |  Strahlentherapie und Onkologie 5 · 2012
Original article
ed in . Tab. 1, referring to the estab-
lished NCCN and German Cancer Soci-
ety guidelines [40].
Results
In the 4-year period from 2005–2008, 
34 patients with LARC were treated with 
neoadjuvant radiotherapy simultaneous 
with capecitabine and oxaliplatin at the 
Radiation Oncology Institute, Univer-
sity Hospital Basel. Chemotherapy was 
administered by the medical oncologists 
from two institutions. Surgery was per-
formed at four different centres with ex-
pertise in rectal cancer, according to the 
patient’s preferences and place of resi-
dence. Retrospective data were collect-
ed and analyzed. Complete follow-up da-
ta up to November 2009 was available for 
31 patients: 2 patients had changed their 
place of residency and 1 refused the fol-
low-up. The mean follow-up for all pa-
tients analyzed and for the patients alive 
was 22 months (range 0–53 months) and 
24 months (range 3–53 months) respec-
tively.
Tumour control
The main patients’ characteristics are 
summarized in the . Tab. 2. None of the 
patients relapsed locally. Five (15%) pa-
tients relapsed with distant metastases 
only. One 28-year-old patient diagnosed 
with a rectal tumour of signet ring adeno-
carcinoma had progressive disease: peri-
toneal carcinomatosis was revealed dur-
ing the scheduled abdominoperineal re-
section (APR). Retrospective assessment 
suggests that the tumour stage was ini-
tially underestimated. The patient died 
shortly afterwards due to progressive dis-
ease. At the time of last follow-up 88% of 
the patients (n = 30) were alive, and 82% 
(n = 28) of all patients analyzed have so 
far faced no failure. Stage regression ac-
cording to UICC-TNM classification 
(. Tab. 3) and pathological regression of 
grade 3 and 4 according to Dworak were 
observed in 18.2% (n = 6) and 15.1% (n = 5) 
respectively (. Tab. 4).
Sphincter-preserving surgery was per-
formed in 75% (n = 25) of all patients who 
underwent surgery and in 53% (n = 8) of 
15 patients with tumour in the lower rec-
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Abstract
Background. Phase II trials of neoadjuvant 
treatment in UICC-TNM stage II and III rec-
tal cancer with capecitabine and oxaliplatin 
demonstrated favourable rates on tumour re-
gression with acceptable toxicity.
Patients and methods. Retrospective eval-
uation of 34 patients treated from 2005–
2008 outside clinical trials (CTR) with neoad-
juvant irradiation (45–50.4 Gy) and simulta-
neous capecitabine 825 mg/m2 b.i.d. on days 
1–14 and 22–35 and oxaliplatin 50 mg/m2 
on days 1, 8, 22 and 29 (CAPOX). Twenty-six 
(77%) patients received one or two courses of 
capecitabine 1,000 mg/m2 b.i.d. on days 1–14 
and oxaliplatin 130 mg/m2 on day 1 (XELOX) 
prior to simultaneous chemoradiotherapy.
Results. UICC-TNM stage regression was ob-
served in 60% (n = 20). Dworak’s regression 
grades 3 and 4 were achieved in 18.2% (n = 6) 
and 15.1% (n = 5) of the patients. Sphincter-
preserving surgery was performed in 53% 
(n = 8) of patients with a tumour of the low-
er rectum. Within the mean observation of 
24 months, none of the patients relapsed lo-
cally, 1 patient had progressive disease and 
5 patients (15%) relapsed distantly. Toxicity 
of grade 3 and 4 was mainly diarrhoea 18% 
(n = 6) and perianal pain 9% (n = 3). Never-
theless, severe cardiac events (n = 2), severe 
electrolyte disturbances (n = 2), and syncopes 
(n = 2) were observed as well.
Conclusion. Treatment efficacy and com-
mon toxicity are similar to the reports of 
phase I/II trials. However, several severe ad-
verse events were observed in our cohort 
study. The predisposing factors for these 
events have yet to be studied and may have 
implications for the selection of patients out-
side CTR.
Keywords
Rectal cancer · Oxaliplatin · Capecitabine · 
Toxicity
Simultane neoadjuvante Radiochemotherapie mit Capecitabin 
und Oxaliplatin beim lokal fortgeschrittenen Rektumkarzinom. 
Therapieergebnisse außerhalb klinischer Studien
Zusammenfassung
Hintergrund. Phase-II-Studien zur neoadju-
vanten Therapie des Rektumkarzinoms (UICC-
TNM-Stadium II und III) mit Capecitabin und 
Oxaliplatin zeigten eine günstige Tumorre-
gressionsrate bei akzeptabler Toxizität.
Patienten und Methoden. Retrospekti-
ve Auswertung der Daten von 34 Patienten 
(Nachsorge . Tab. 1, Patientencharakteristi-
ka . Tab. 2), die in den Jahren 2005–2008 au-
ßerhalb klinischer Studien eine neoadjuvan-
te Strahlentherapie (45–50,4 Gy) simultan 
mit Capecitabin 825 mg/m2 2-mal täglich an 
den Tagen 1–14 und 22–35 und Oxaliplatin 
50 mg/m2 an den Tagen 1, 8, 22 und 29 (CA-
POX) erhielten. 26 (77%) Patienten bekamen 
1–2 Zyklen Capecitabin 1000 mg/m2 2-mal 
täglich an den Tagen 1–14 und Oxaliplatin 
130 mg/m2 am Tag 1 (XELOX) vor der simulta-
nen Chemoradiotherapie.
Ergebnisse. Eine Regression des UICC-TNM-
Stadiums wurde bei 60% (n = 20) beobach-
tet (. Tab. 3). Regressionsgrade 3 und 4 nach 
Dworak wurden in 18,2% (n = 6) und 15,1% 
(n = 5) der Patienten erreicht (. Tab. 4). Ei-
ne sphinktererhaltende Operation wurde in 
53% (n = 8) der Patienten mit einem dista-
len Tumor realisiert. Innerhalb der Beobach-
tungszeit von 24 Monaten erlitt keiner der 
Patienten einen lokalen Rückfall. Eine Pati-
entin zeigte eine kontinuierliche Tumorpro-
gression und 5 Patienten (15%) entwickelten 
Fernmetastasen im Verlauf. Toxizität (. Tab. 5) 
vom Grad (G) 3/4 manifestierte sich über-
wiegend als Diarrhoe 18% (n = 6) und peria-
naler Schmerz 9% (n = 3). Es traten jedoch 2 
schwerwiegende kardiale Ereignisse, 2 Fäl-
le von schwerer Elektrolytentgleisung und 
2 Synkopen auf.
Schlussfolgerung. Die Effektivität und die 
allgemeine Toxizität in unserem Patienten-
gut sind den Ergebnissen aus den Phase-I/
II-Studien ähnlich. Es traten jedoch einzelne 
schwerwiegende Nebenwirkungen in unse-
rer Kohorte auf. Die hierzu beitragenden Fak-
toren bedürfen einer weiteren Beobachtung 
und können Konsequenzen für die künftige 
Patientenselektion haben.
Schlüsselwörter
Rektumkarzinom · Oxaliplatin · Capecitabin · 
Toxizität
Abstract · Zusammenfassung
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tum. Complete tumour resection was 
achieved in 31 of 33 patients undergoing 
surgery (94%).
Toxicity
Treatment-related toxicity in the neoad-
juvant setting was predominantly mild 
(. Tab. 5). Toxicity of grade 0–2 was 
mainly diarrhoea 71% (n = 24), dysuria 
59% (n = 20), paraesthesia 32% (n = 11), 
haematological abnormalities 38% (n = 13) 
and local skin reactions 29% (n = 10). Se-
vere diarrhoea, skin and haematological 
toxicities were rare. However, there were 
few but severe treatment-related compli-
cations.
Two patients, who had had a previous 
myocardial infarction, experienced a sec-
ond myocardial infarction immediately 
after the first course of chemotherapy be-
fore starting combined RCT. One of them 
died due to this event. The other contin-
ued treatment with modified chemothera-
py. There were two cases with severe elec-
trolyte imbalances, two syncopes and one 
case of deep venous thrombosis of lower 
extremities. One patient had developed a 
generalized skin rash, which regressed af-
ter capecitabine was withdrawn. Another 
patient with severe diarrhoea refused ear-
lier hospitalisation as well as offered med-
ication. He passed through severe dehy-
dration, electrolyte disturbance, acute re-
nal insufficiency and urosepsis.
Treatment modification (either of che-
motherapy or of radiotherapy or both) 
was necessary in order to prevent or re-
duce severe toxicity in 32% of the cases 
(n = 11), with dose reduction of the che-
motherapy agents by more than 25% of 
the originally planned dose in 18% (n = 6) 
of the patients. Due to treatment-related 
toxicity 3 patients had an interruption in 
radiotherapy of 1–3 days, and in anoth-
er 3 cases radiotherapy was discontinued 
earlier than intended.
Discussion
The results of our retrospective evaluation 
of patients treated preoperatively with ir-
radiation in combination with capecitabi-
ne and oxaliplatin for LARC outside CTR 
demonstrate similar results as the report-
ed phase I and II trials in terms of down-
staging and down-sizing, pathological re-
gression, sphincter preservation rate, rates 
of complete resection, local and distant 
control [9, 17, 21, 26, 29, 35, 36]. However, 
these parameters of treatment efficacy did 
not differ markedly from those reported in 
the trials for simultaneous irradiation with 
administration of either capecitabine sole-
ly or 5-FU with leucovorin [12, 13, 22, 23, 
25]. Hence according to our data and to the 
published phase I and II trials a definitive 
conclusion favouring one of these treat-
ment approaches could not be made so far. 
Moreover, one lethal treatment-related and 
several life-threatening toxicities occurred 
in our patient cohort, similar to the trial 
from Chua et al. [9], who initially did not 
systematically exclude patients with a pre-
vious history of cardiovascular disease. The 
latter study counts even higher rates of fa-
tal and life-threatening events: 9 thrombo-
embolic and cardiac events, 4 of them le-
thal. Comparable to our observation, cardi-
ac events occurred during administration 
of XELOX regimen, before the start of si-
multaneous CAPOX regimen and irradi-
ation. In several other phase I and II tri-
als using capecitabine and oxaliplatin with 
thoroughly selected patient populations, 
cardiovascular events occurred as well [17, 
21, 26, 29, 34, 35, 36].
The reported incidence of 5-FU-in-
duced cardiac events ranges from 1.2–
Tab. 5 Acute toxicity
NCI CTC Grade
Toxicity Grade 1–2
(n, %)
Grade 3
(n, %)
Grade 4
(n, %)
Hematologic
Leucopenia 7 (21) 0 0
Thrombocytopenia 9 (27) 1 (3) 0
Anaemia 6 (18) 0 0
Neurologic
Paresthesia/dysesthesia 11 (32) 0 0
Skin
Local toxicity, perianal 10 (39) 2 (6) 0
Hand–foot syndrome 3 (9) 0 0
Allergy (skin rash/exanthema) 1 (3) 0 0
Genitourinary
Dysuria/pollakisuria 20 (59) 0 0
Renal insufficiency 0 1 (3) 0
Vaginal mycosis 1 (3) 0 0
Gastrointestinal
Diarrhoea 24 (71) 6 (18) 0
Obstipation 3 (9) 0 0
Nausea 3 (9) 0 0
Anorexia 6 (18) 0 0
Body weight reduction 2 (6) 0 0
Proctitis 7 (21) 0 0
Cholangitis 1 (3) 0 0
Other
Pain 3 (9) 3 (9) 0
Deep venous thrombosis 0 1 (3) 0
Syncope 0 2 (6) 0
Fatigue 8 (24) 1(3) 0
Infection 3 (9) 0 1(3)
Cardiovascular 0 0 2a (6)
Electrolyte dysbalance
Hypokalemia 2 (6) 0 1(3)
Hyponatremia 1 (3) 1(3) 0
aOne non-lethal myocardial infarction, one acute cardiac insufficiency with sudden death.
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18% [27, 28]. In the study of Van Cut-
sem et al. [42], capecitabine monothera-
py was compared with 5-FU and leucovo-
rin (Mayo Clinic regimen), yielding similar 
rates of cardiac events (3% for each arm). 
The mechanism of cardiac toxicity either 
with 5-FU infusion or with capecitabine 
was closely investigated. It is believed to be 
primarily based on coronary vasospasm [1, 
18]. Whether the addition of oxaliplatin to 
capecitabine increases the risk for cardio-
vascular toxicity remains to be elucidated. 
In a retrospective evaluation Ng et al. [31] 
concluded that cardiotoxicity of the combi-
nation with oxaliplatin exceeds the toxicity 
of capecitabine monotherapy. In our study, 
severe cardiac events occurred in 2 of 34 
patients (6%) during administration of the 
XELOX scheme, prior to irradiation. This 
may be related either to the higher doses 
of capecitabine and oxaliplatin adminis-
tered in the XELOX scheme compared to 
the CAPOX scheme, or to the timing of the 
first exposition to these substances.
Other rare, severe side effects were two 
episodes of syncope during the simultane-
ous chemoradiotherapy, in one case due 
to severe electrolyte imbalance. The elec-
trolyte imbalances are known to be asso-
ciated with administration of capecitabi-
ne or 5-FU with and without oxaliplatin-
based chemotherapy, but may be induced 
primarily by oxaliplatin [3].
The side effects noticed in our study 
raise caution for the wide application of 
this treatment scheme without a careful 
selection of patients, particularly among 
elderly patients [16]. Currently available 
data remains controversial and do not yet 
provide a clear conclusion whether treat-
ment efficacy outweighs the risk of higher 
toxicity. The previously reported superi-
ority of neoadjuvant chemoradiaotherapy 
for LARC with capecitabine and oxalipla-
tin compared to the results of trials with 
either 5 FU or capecitabine monotherapy 
was not observed in the latest phase II trial 
by Öfner et al. [32]. Moreover, the phase III 
STAR-01 (Studio Terapia Adiuvante Ret-
to) trial reported increased treatment-
related toxicity following the addition of 
oxaliplatin to 5-FU without affecting pri-
mary tumour response [2]. On the other 
hand, in a phase III trial by Gérard et al. 
[19], a trend to higher rates of complete 
tumour regression was seen in the com-
bination of oxaliplatin with capecitabine 
in comparison to capecitabine alone. The 
rates of complete and near complete tu-
mour regression in the capecitabine and 
oxaliplatin arm were similar to those in 
our present study. However, again in line 
with our findings, increased high grade 
toxicity was noted by Gérard et al. [19] in 
the combined oxaliplatin arm. Thus, the 
yet awaited results of the large random-
ized phase III 4-arm NSABP (National 
Surgical Adjuvant Breast and Bowel Proj-
ect) R-04 trial aiming to compare simulta-
neous radiation for resectable rectal can-
cer either with capecitabine or 5-FU with 
or without oxaliplatin may provide fur-
ther help for the evaluation of chemora-
diotherapy treatment options for LARC 
[46].
Thus, outside clinical trials in a non-re-
stricted patient population, the combina-
tion of capecitabine and oxaliplatin dem-
onstrates favourable results in terms of 
complete response, tumour down-stag-
ing and down-sizing in order to facilitate 
a sphincter- and/or organ-preserving sur-
gery without compromising local tumour 
control. However, the rate of distant me-
tastases still remains high.
Conclusion
Considering several severe complica-
tions observed in our analysis and in the 
previous phase I/II studies while miss-
ing clear tumour-related superiority in 
the latest randomized phase III trial, cau-
tion should be taken when administer-
ing XELOX or CAPOX outside clinical trials 
for LARC. In particular, cardiac morbidi-
ty should be thoroughly assessed before 
envisaging a combined capecitabine and 
oxaliplatin treatment.
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